SWX:NWRN

Stock Analysis Report

Executive Summary

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally.

Snowflake

Fundamentals

Flawless balance sheet with exceptional growth potential.

Risks

  • Newron Pharmaceuticals has significant price volatility in the past 3 months.

Share Price & News

How has Newron Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.2%

SWX:NWRN

-0.06%

CH Pharmaceuticals

0.5%

CH Market


1 Year Return

-47.8%

SWX:NWRN

9.0%

CH Pharmaceuticals

3.1%

CH Market

NWRN underperformed the Pharmaceuticals industry which returned 9% over the past year.

NWRN underperformed the Market in Switzerland which returned 3.1% over the past year.


Share holder returns

NWRNIndustryMarket
7 Day-2.2%-0.06%0.5%
30 Day0%-0.4%-0.8%
90 Day-27.2%4.0%1.9%
1 Year-47.8%-47.8%18.8%9.0%8.4%3.1%
3 Year-71.5%-71.5%31.1%12.5%30.6%17.3%
5 Year-64.3%-64.3%30.8%5.5%33.2%12.6%

Price Volatility Vs. Market

How volatile is Newron Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Newron Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Newron Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).

Newron Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Newron Pharmaceuticals is loss making, we can't compare its value to the Europe Pharmaceuticals industry average.

Newron Pharmaceuticals is loss making, we can't compare the value of its earnings to the Switzerland market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Newron Pharmaceuticals, we can't assess if its growth is good value.


Price Based on Value of Assets

Newron Pharmaceuticals is good value based on assets compared to the CH Pharmaceuticals industry average.


Next Steps

Future Growth

How is Newron Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

63.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Newron Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.

Newron Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.

Newron Pharmaceuticals's revenue growth is expected to exceed the Switzerland market average.

Newron Pharmaceuticals's earnings growth is expected to exceed the Switzerland market average.

Newron Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 3.3%.


Earnings per Share Growth Estimates


Future Return on Equity

Newron Pharmaceuticals is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).


Next Steps

Past Performance

How has Newron Pharmaceuticals performed over the past 5 years?

-2.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Newron Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Newron Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Newron Pharmaceuticals's 1-year growth to the Europe Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Newron Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Newron Pharmaceuticals has efficiently used its assets last year compared to the Europe Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Newron Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Newron Pharmaceuticals's financial position?


Financial Position Analysis

Newron Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Newron Pharmaceuticals's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Newron Pharmaceuticals has no debt.

Newron Pharmaceuticals has no debt compared to 5 years ago when it was 6.8%.


Balance Sheet

Low level of unsold assets.

Newron Pharmaceuticals has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Newron Pharmaceuticals has sufficient cash runway for 2.7 years based on current free cash flow.

Newron Pharmaceuticals has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of -3% each year.


Next Steps

Dividend

What is Newron Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Newron Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Newron Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Newron Pharmaceuticals has not reported any payouts.

Unable to verify if Newron Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Newron Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Newron Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Switzerland.


Next Steps

Management

What is the CEO of Newron Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

7.2yrs

Average management tenure


CEO

Stefan Weber (54yo)

7.2yrs

Tenure

€647,000

Compensation

Mr. Stefan Weber serves as the Chief Financial Officer and Finances and Administration Director at Duktus S.A. Mr. Weber has been the Chief Executive Officer of Newron Pharmaceuticals SpA since June 1, 201 ...


CEO Compensation Analysis

Stefan's remuneration is about average for companies of similar size in Switzerland.

Stefan's compensation has increased whilst company is loss making.


Management Age and Tenure

7.2yrs

Average Tenure

62yo

Average Age

The average tenure for the Newron Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

7.0yrs

Average Tenure

62.5yo

Average Age

The tenure for the Newron Pharmaceuticals board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Stefan Weber (54yo)

    CEO & Executive Director

    • Tenure: 7.2yrs
    • Compensation: €647.00k
  • Marco Caremi (62yo)

    Executive Vice President of Business Development

    • Tenure: 7.2yrs
  • Ravi Anand (62yo)

    Chief Medical Officer

    • Tenure: 14.3yrs
    • Compensation: €1.07m
  • Dennis Dionne (69yo)

    Vice President of Commercial Affairs

    • Tenure: 4.6yrs
  • Roberto Galli

    Vice President of Finance

    • Tenure: 7.2yrs

Board Members

  • Patrick Langlois (74yo)

    Non-Executive Director

    • Tenure: 11.1yrs
    • Compensation: €98.00k
  • Don deBethizy (69yo)

    Non-Executive Director

    • Tenure: 5.4yrs
    • Compensation: €95.00k
  • Stefan Weber (54yo)

    CEO & Executive Director

    • Tenure: 7.2yrs
    • Compensation: €647.00k
  • Ulrich Köstlin (67yo)

    Non-Executive Chairman

    • Tenure: 6.3yrs
    • Compensation: €118.00k
  • Luca Benatti (58yo)

    Non-Executive Director

    • Tenure: 5.4yrs
    • Compensation: €96.00k
  • Ze’ Seltzer

    Member of Scientific & Clinical Advisory Board

    • Tenure: 0.0yrs
  • Fabrizio Stocchi

    Member of Scientific and Clinical Advisory Board

    • Tenure: 0.0yrs
  • Emilio Perucca

    Member of Scientific & Clinical Advisory Board

    • Tenure: 0.0yrs
  • Paolo Marchettini

    Member of Scientific & Clinical Advisory Board

    • Tenure: 0.0yrs
  • Richard Murphy (55yo)

    Chairman of the Board of Statutory Auditors

    • Tenure: 12.3yrs
    • Compensation: €13.00k

Company Information

Newron Pharmaceuticals S.p.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Newron Pharmaceuticals S.p.A.
  • Ticker: NWRN
  • Exchange: SWX
  • Founded: 1998
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CHF104.931m
  • Shares outstanding: 17.85m
  • Website: https://www.newron.com

Number of Employees


Location

  • Newron Pharmaceuticals S.p.A.
  • Via Ludovico Ariosto 21
  • Bresso
  • Milan
  • 20091
  • Italy

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NWRNSWX (SIX Swiss Exchange)YesOrdinary SharesCHCHFDec 2006
NP5DB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 2006
NWPH.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDDec 2006
NP5XTRA (XETRA Trading Platform)YesOrdinary SharesDEEURDec 2006
0QOILSE (London Stock Exchange)YesOrdinary SharesGBCHFDec 2006

Biography

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral ne ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/20 21:01
End of Day Share Price2019/08/20 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.